Introduction
============

Ventilator-associated pneumonia (VAP) is the most common nosocomial infection among ventilated patients and is associated with increased mortality and morbidity \[[@B1]\]. Oral chlorhexidine has been used to decontaminate the airway in critically ill patients, as studies suggest a risk reduction in VAP \[[@B2]\]. Chlorhexidine reacts with soaps in toothpaste to form inactive insoluble salts \[[@B3]\]. A minimum delay of 30 minutes between tooth brushing and the subsequent application of chlorhexidine is therefore recommended \[[@B4]\].

Methods
=======

A telephone questionnaire was conducted on all ICUs in the UK to assess current oral decontamination procedures with regards to chlorhexidine use and the timing of tooth brushing with toothpaste.

Results
=======

Sixty-five per cent of ICUs in the UK responded to our survey (*n*= 157). Ninety-seven per cent (*n*= 152) used chlorhexidine and 96% (*n*= 150) used it as part of a ventilator care bundle. Forty-six per cent (*n =*70) used a gel, 32% (*n =*48) used a mouthwash and 23% (*n =*34) used both preparations. The frequency of chlorhexidine application varied between ICUs; 15 (9.9%) applied 4-hourly, 91 (59.9%) 6-hourly, 20 (13.2%) 8-hourly, 19 (12.5%) 12-hourly and seven (4.6%) applied at variable times. Ninety-seven per cent (*n*= 152) brushed patient\'s teeth; 86% (*n*= 130) used toothpaste, 3% (*n*= 5) used chlorhexidine gel and 11% (*n*= 17) used both. Ninety-seven per cent (*n*= 147) of ICUs using chlorhexidine also brushed patient\'s teeth with toothpaste. Forty-eight per cent (*n*= 70) administered chlorhexidine within 30 minutes of toothpaste application (Table [1](#T1){ref-type="table"}).

###### 

Timing difference between toothpaste and chlorhexidine (minutes)

  Minutes    Number of ICUs (%)
  ---------- --------------------
  \>30       74 (50.3%)
  \<30       32 (21.8%)
  Nil        38 (25.9%)
  Variable   3 (2.0%)

Conclusion
==========

Chlorhexidine is being used too soon after the application of toothpaste in 48% of ICUs in the UK. This results in attenuation of its effect and may remove its beneficial risk reduction in VAP. Awareness of this interaction should be emphasised.
